A Phase 1/2, Open Label, Non-Randomized Dose Escalation Study to Evaluate the Safety, Tolerability, Immune Response and Clinical Response of Multiple Doses of MKC1106-MT in Subjects With Advanced Melanoma.
Phase of Trial: Phase I/II
Latest Information Update: 02 Aug 2010
At a glance
- Drugs MKC 1106-MT (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors MannKind Corporation
- 31 Aug 2018 Biomarkers information updated
- 02 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Aug 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.